Adverse events mainly consisted of injection site pain, which occurred significantly more in patients receiving galcanezumab vs placebo. Injection site erythema was much more common in the galcanezumab 240 mg group compared with placebo. Limitations on this study include restrictive criteria for inclusion that preclude result generalizability.

Related Articles

The study researchers conclude that “[galcanezumab] treatment was associated with a statistically significant and clinically meaningful reduction in monthly [migraine headache days] at doses of 120 and 240 mg given subcutaneously once monthly. Moreover, patients treated with either dose of galcanezumab reported a reduction in the migraine-related impairment of function and a significant reduction in migraine-related disability, while also reducing the use of acute migraine medications.”